デフォルト表紙
市場調査レポート
商品コード
1412844

長時間作用型避妊薬市場:タイプ、製品、用途、最終用途別-2024~2030年の世界予測

Long-acting Contraception Market by Type (Long-Acting Contraceptives, Short-Acting Contraceptives), Product (Injectables, Intrauterine Devices, Subdermal Implants), Application, End-use - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 191 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
長時間作用型避妊薬市場:タイプ、製品、用途、最終用途別-2024~2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 191 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

長時間作用型避妊薬市場規模は2023年に34億2,000万米ドルと推計され、2024年には36億8,000万米ドルに達し、CAGR 7.06%で2030年には55億2,000万米ドルに達すると予測されます。

長時間作用型避妊薬の世界市場

主な市場の統計
基準年[2023] 34億2,000万米ドル
予測年[2024] 36億8,000万米ドル
予測年 [2030] 55億2,000万米ドル
CAGR(%) 7.06%
長時間作用型避妊薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは長時間作用型避妊薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、長時間作用型避妊薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-長時間作用型避妊薬市場の市場規模および予測は?

2-長時間作用型避妊薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-長時間作用型避妊薬市場における技術動向と規制の枠組みは?

4-長時間作用型避妊薬市場における主要ベンダーの市場シェアは?

5-長時間作用型避妊薬市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 男性と女性の間で長期避妊の採用が増加
      • 公的資金による家族計画サービスの増加
    • 抑制要因
      • 長期避妊に伴う副作用
    • 機会
      • 技術的に進歩した長期避妊法のイントロダクション
      • LTCに対する政府の強力な支援
    • 課題
      • 限られた承認製品に対する懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 長時間作用型避妊薬市場:タイプ別

  • 長時間作用型避妊薬
  • 短時間作用型避妊薬

第7章 長時間作用型避妊薬市場:製品別

  • 注射剤
  • 子宮内器具
  • 皮下インプラント

第8章 長時間作用型避妊薬市場:用途別

  • 避妊
  • HIV
  • 統合失調症

第9章 長時間作用型避妊薬市場:最終用途別

  • ドラッグストア
  • eコマース
  • 病院

第10章 南北アメリカの長時間作用型避妊薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の長時間作用型避妊薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの長時間作用型避妊薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Bayer AG
    • DKT International
    • HRA Pharma SAS by Perrigo Company plc
    • Merck & Co., Inc.
    • Meril Life Sciences Pvt. Ltd.
    • Mona Lisa N.V.
    • OCON Healthcare
    • Pfizer Inc.
    • Pregna International Limited
    • Prosan International B.V.
    • SMB Corporation of India
    • Teva Pharmaceuticals Industries Ltd.
    • The Cooper Companies, Inc.
    • Viatris Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. LONG-ACTING CONTRACEPTION MARKET RESEARCH PROCESS
  • FIGURE 2. LONG-ACTING CONTRACEPTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. LONG-ACTING CONTRACEPTION MARKET DYNAMICS
  • FIGURE 7. LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 14. LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. LONG-ACTING CONTRACEPTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-ACTING CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-ACTING CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 9. LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBDERMAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. LONG-ACTING CONTRACEPTION MARKET SIZE, BY CONTRACEPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. LONG-ACTING CONTRACEPTION MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. LONG-ACTING CONTRACEPTION MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. LONG-ACTING CONTRACEPTION MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. LONG-ACTING CONTRACEPTION MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 189. LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. LONG-ACTING CONTRACEPTION MARKET LICENSE & PRICING
目次
Product Code: MRR-563BF1FD02DB

[191 Pages Report] The Long-acting Contraception Market size was estimated at USD 3.42 billion in 2023 and expected to reach USD 3.68 billion in 2024, at a CAGR 7.06% to reach USD 5.52 billion by 2030.

Global Long-acting Contraception Market

KEY MARKET STATISTICS
Base Year [2023] USD 3.42 billion
Estimated Year [2024] USD 3.68 billion
Forecast Year [2030] USD 5.52 billion
CAGR (%) 7.06%
Long-acting Contraception Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Long-acting Contraception Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Long-acting Contraception Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Long-acting Contraception Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, DKT International, HRA Pharma SAS by Perrigo Company plc, Merck & Co., Inc., Meril Life Sciences Pvt. Ltd., Mona Lisa N.V., OCON Healthcare, Pfizer Inc., Pregna International Limited, Prosan International B.V., SMB Corporation of India, Teva Pharmaceuticals Industries Ltd., The Cooper Companies, Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Long-acting Contraception Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Long-Acting Contraceptives
    • Short-Acting Contraceptives
  • Product
    • Injectables
    • Intrauterine Devices
    • Subdermal Implants
  • Application
    • Contraception
    • HIV
    • Schizophrenia
  • End-use
    • Drug Store
    • E-Commerce
    • Hospital
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Long-acting Contraception Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Long-acting Contraception Market?

3. What are the technology trends and regulatory frameworks in the Long-acting Contraception Market?

4. What is the market share of the leading vendors in the Long-acting Contraception Market?

5. Which modes and strategic moves are suitable for entering the Long-acting Contraception Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Long-acting Contraception Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising adoption of long term contraception among male and female
      • 5.1.1.2. Rising publicly funded family planning services
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects of long term contraception
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of technically advanced long term contraception methods
      • 5.1.3.2. Strong government support for LTC
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding limited approved products
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Long-acting Contraception Market, by Type

  • 6.1. Introduction
  • 6.2. Long-Acting Contraceptives
  • 6.3. Short-Acting Contraceptives

7. Long-acting Contraception Market, by Product

  • 7.1. Introduction
  • 7.2. Injectables
  • 7.3. Intrauterine Devices
  • 7.4. Subdermal Implants

8. Long-acting Contraception Market, by Application

  • 8.1. Introduction
  • 8.2. Contraception
  • 8.3. HIV
  • 8.4. Schizophrenia

9. Long-acting Contraception Market, by End-use

  • 9.1. Introduction
  • 9.2. Drug Store
  • 9.3. E-Commerce
  • 9.4. Hospital

10. Americas Long-acting Contraception Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Long-acting Contraception Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Long-acting Contraception Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. AbbVie Inc.
    • 14.1.2. Bayer AG
    • 14.1.3. DKT International
    • 14.1.4. HRA Pharma SAS by Perrigo Company plc
    • 14.1.5. Merck & Co., Inc.
    • 14.1.6. Meril Life Sciences Pvt. Ltd.
    • 14.1.7. Mona Lisa N.V.
    • 14.1.8. OCON Healthcare
    • 14.1.9. Pfizer Inc.
    • 14.1.10. Pregna International Limited
    • 14.1.11. Prosan International B.V.
    • 14.1.12. SMB Corporation of India
    • 14.1.13. Teva Pharmaceuticals Industries Ltd.
    • 14.1.14. The Cooper Companies, Inc.
    • 14.1.15. Viatris Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing